ArticleAmerican journal of cancer research2026
Efficacy of tislelizumab combined with nab-paclitaxel and nedaplatin in advanced esophageal squamous cell carcinoma and its impact on serum tumor markers.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of tislelizumab combined with nab-paclitaxel plus nedaplatin for advanced esophageal squamous cell carcinoma (ESCC), and its effects on serum tumor markers and inflammatory cytokines.
methodsA total of 228 advanced ESCC patients were retrospectively enrolled and divided into an observation group (tislelizumab combined with nab-paclitaxel plus nedaplatin, n=114) and a control group (chemotherapy alone: nab-paclitaxel plus nedaplatin, n=114). Related serological indicators, T lymphocyte subsets, quality of life, short-term efficacy, pathological response, survival outcomes and adverse reactions were compared. Independent prognostic factors were analyzed via univariate and multivariate Cox regression.
resultsAfter treatment, both groups exhibited decreased levels of tumor markers, inflammatory cytokines, soluble PD-1, PD-L1, VEGF and MMP-9, with lower levels in the observation group (all P<0.05). The observation group had improved immune function, higher SF-36 scores, as well as higher objective response rate, disease control rate, and pathological response indexes (all P<0.05). Moreover, patients in the observation group had longer progression-free survival and overall survival (both P<0.05). Advanced TNM stage was an adverse prognostic factor, while combined immunochemotherapy reduced mortality risk.
conclusionTislelizumab plus the dual chemotherapy regimen can effectively reduce serum tumor markers and alleviate tumor-related inflammation, improve immune status, quality of life and survival of patients with advanced ESCC with acceptable safety, supporting its potential for broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.